VanEck Associates
CVAC

VanEck Associates’s CureVac CVAC Stock Holding History

VanEck Associates’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,413
Closed -$7K – 1397
2024
Q3 		$7K Sell
2,413
-1,047
-30% -$3.45K ﹤0.01% 1345
2024
Q2 		$12K Hold
3,460
– – ﹤0.01% 1336
2024
Q1 		$10K Buy
3,460
+700
+25% +$2.46K ﹤0.01% 1328
2023
Q4 		$12K Buy
2,760
+377
+16% +$2.04K ﹤0.01% 1341
2023
Q3 		$16K Buy
2,383
+427
+22% +$3.77K ﹤0.01% 1342
2023
Q2 		$20K Sell
1,956
-248
-11% -$2.22K ﹤0.01% 1347
2023
Q1 		$15K Buy
2,204
+635
+40% +$5.54K ﹤0.01% 1362
2022
Q4 		$9K Buy
1,569
+427
+37% +$3.15K ﹤0.01% 1375
2022
Q3 		$9K Buy
+1,142
New +$13.3K ﹤0.01% 1339

Other funds holding CVAC

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

VanEck Associates's CVAC Position: Q4 2024 in Review

VanEck Associates sold out of CureVac (CVAC) in Q4 2024, closing a stake of 2,413 shares — an estimated $7K sold.

VanEck Associates first reported a position in CVAC in Q3 2022 and held it in 9 quarters. The position peaked at $20K in Q2 2023. 75 funds tracked by Wall St. Rank hold CVAC as of Q4 2024.

  • VanEck Associates reported no remaining CureVac position as of Q4 2024 after selling out during the quarter.
  • VanEck Associates sold 2,413 CureVac shares in Q4 2024, an estimated $7K.
  • VanEck Associates first reported a position in CureVac in Q3 2022 and held it in 9 quarters.
  • VanEck Associates's CureVac position peaked at $20K in Q2 2023.
  • 75 funds tracked by Wall St. Rank held CureVac as of Q4 2024.

Based on VanEck Associates's 13F filing for Q4 2024, filed 29 Jan 2025.